Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation

$48.00 plus tax (Refund Policy)

Download / Buy Article:


Objective: Clozapine and risperidone were the first two antipsychotic drugs of a new class of agents for the pharmacotherapy of schizophrenia. It has been suggested that refractory schizophrenic patients who fail to respond to neither clozapine nor risperidone may respond to a combination/augmentation strategy of both medicaments.

Method: Three cases of individuals with unremittent schizophrenia treated via this combination are presented. Response was evaluated by clinical follow‐up and PANSS rating scale.

Results: Good clinical results with no noticeable adverse side effects, ascertained by a reduction from baseline scores of the Positive and Negative Syndrome Scale (PANSS) were obtained in all three patients.

Conclusions: The findings from this pilot study suggest this combination as a possible therapeutic approach for treating resistant schizophrenic patients.

Keywords: augmentation; clozapine; risperidone; schizophrenia

Document Type: Research Article


Publication date: April 1, 2000

Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more